{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:49:56Z","timestamp":1780091396901,"version":"3.54.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ITMO Cancer","award":["21CD125-00"],"award-info":[{"award-number":["21CD125-00"]}]},{"name":"ITMO Cancer","award":["21CD125-00"],"award-info":[{"award-number":["21CD125-00"]}]},{"name":"Association Fran\u00e7aise pour l\u2019\u00e9tude du Foie"},{"DOI":"10.13039\/501100014182","name":"Cancerop\u00f4le Provence-Alpes-C\u00f4te d\u2019Azur","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014182","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007391","name":"Association pour la Recherche sur le Cancer","doi-asserted-by":"publisher","award":["ARCPGA2023010005822_6352"],"award-info":[{"award-number":["ARCPGA2023010005822_6352"]}],"id":[{"id":"10.13039\/100007391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"INCa","doi-asserted-by":"crossref","award":["2020-11\/279\/NI-KA"],"award-info":[{"award-number":["2020-11\/279\/NI-KA"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02391-w","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T12:18:20Z","timestamp":1759407500000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Establishment of a mouse hepatocellular carcinoma tumoroid panel recapitulating inter- and intra- heterogeneity for disease modelling and combinatorial drug discovery"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4172-7866","authenticated-orcid":false,"given":"Margherita","family":"Grattarola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1691-3915","authenticated-orcid":false,"given":"Nicolas","family":"Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriane","family":"Cannet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00fcge","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2334-3121","authenticated-orcid":false,"given":"Abdessamad El","family":"Kaoutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5359-6504","authenticated-orcid":false,"given":"Christian","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Dobric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8418-3382","authenticated-orcid":false,"given":"Jean-Paul","family":"Borg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6409-3910","authenticated-orcid":false,"given":"Celia","family":"Sequera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6100-4695","authenticated-orcid":false,"given":"Flavio","family":"Maina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"issue":"3","key":"2391_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2391_CR2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","volume":"161","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Ferlay J, de Martel C, Georges D, Ibrahim AS, Zheng R, et al. Global, regional and National burden of primary liver cancer by subtype. Eur J Cancer. 2022;161:108\u201318.","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"2391_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/liv.14865","volume":"41","author":"R Sartoris","year":"2021","unstructured":"Sartoris R, Gregory J, Dioguardi Burgio M, Ronot M, Vilgrain V. HCC advances in diagnosis and prognosis: digital and imaging. Liver Int. 2021;41(Suppl 1):73\u20137.","journal-title":"Liver Int"},{"issue":"4","key":"2391_CR4","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jhep.2021.07.004","volume":"75","author":"J Bruix","year":"2021","unstructured":"Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol. 2021;75(4):960\u201374.","journal-title":"J Hepatol"},{"issue":"2","key":"2391_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ccell.2024.01.007","volume":"42","author":"X Yang","year":"2024","unstructured":"Yang X, Yang C, Zhang S, Geng H, Zhu AX, Bernards R, et al. Precision treatment in advanced hepatocellular carcinoma. Cancer Cell. 2024;42(2):180\u201397.","journal-title":"Cancer Cell"},{"issue":"2","key":"2391_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ccell.2019.07.001","volume":"36","author":"Z Qiu","year":"2019","unstructured":"Qiu Z, Li H, Zhang Z, Zhu Z, He S, Wang X, et al. A Pharmacogenomic landscape in human liver cancers. Cancer Cell. 2019;36(2):179\u201393. e11.","journal-title":"Cancer Cell"},{"issue":"9","key":"2391_CR7","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1158\/0008-5472.CAN-13-2971","volume":"74","author":"JL Wilding","year":"2014","unstructured":"Wilding JL, Bodmer WF. Cancer cell lines for drug discovery and development. Cancer Res. 2014;74(9):2377\u201384.","journal-title":"Cancer Res"},{"issue":"6","key":"2391_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.tibtech.2013.03.006","volume":"31","author":"A Mitra","year":"2013","unstructured":"Mitra A, Mishra L, Li S. Technologies for deriving primary tumor cells for use in personalized cancer therapy. Trends Biotechnol. 2013;31(6):347\u201354.","journal-title":"Trends Biotechnol"},{"issue":"45","key":"2391_CR9","doi-asserted-by":"publisher","first-page":"6915","DOI":"10.3748\/wjg.14.6915","volume":"14","author":"MW Leenders","year":"2008","unstructured":"Leenders MW, Nijkamp MW, Borel Rinkes IH. Mouse models in liver cancer research: a review of current literature. World J Gastroenterol. 2008;14(45):6915\u201323.","journal-title":"World J Gastroenterol"},{"key":"2391_CR10","doi-asserted-by":"crossref","unstructured":"Begley DA, Krupke DM, Sundberg JP, Jocoy EL, Richardson JE, Neuhauser SB et al. The mouse models of human cancer database (MMHCdb). Dis Model Mech. 2023;16(4).","DOI":"10.1242\/dmm.050001"},{"issue":"8","key":"2391_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrd1470","volume":"3","author":"I Kola","year":"2004","unstructured":"Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):711\u20135.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2391_CR12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bcp.2013.06.020","volume":"87","author":"BA Ruggeri","year":"2014","unstructured":"Ruggeri BA, Camp F, Miknyoczki S. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. Biochem Pharmacol. 2014;87(1):150\u201361.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2391_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12967-017-1328-z","volume":"15","author":"G Miserocchi","year":"2017","unstructured":"Miserocchi G, Mercatali L, Liverani C, De Vita A, Spadazzi C, Pieri F, et al. Management and potentialities of primary cancer cultures in preclinical and translational studies. J Transl Med. 2017;15(1):229.","journal-title":"J Transl Med"},{"issue":"5","key":"2391_CR14","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.celrep.2018.07.001","volume":"24","author":"S Nuciforo","year":"2018","unstructured":"Nuciforo S, Fofana I, Matter MS, Blumer T, Calabrese D, Boldanova T, et al. Organoid models of human liver cancers derived from tumor needle biopsies. Cell Rep. 2018;24(5):1363\u201376.","journal-title":"Cell Rep"},{"issue":"12","key":"2391_CR15","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/nm.4438","volume":"23","author":"L Broutier","year":"2017","unstructured":"Broutier L, Mastrogiovanni G, Verstegen MM, Francies HE, Gavarro LM, Bradshaw CR, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med. 2017;23(12):1424\u201335.","journal-title":"Nat Med"},{"key":"2391_CR16","doi-asserted-by":"crossref","unstructured":"Beutel AK, Schutte L, Scheible J, Roger E, Muller M, Perkhofer L et al. A prospective feasibility trial to challenge Patient-Derived pancreatic cancer organoids in predicting treatment response. Cancers (Basel). 2021;13(11).","DOI":"10.3390\/cancers13112539"},{"issue":"5","key":"2391_CR17","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.stem.2021.04.005","volume":"28","author":"A Marsee","year":"2021","unstructured":"Marsee A, Roos FJM, Verstegen MMA, Consortium HPBO, Gehart H, de Koning E, et al. Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids. Cell Stem Cell. 2021;28(5):816\u201332.","journal-title":"Cell Stem Cell"},{"issue":"7","key":"2391_CR18","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s12276-024-01272-5","volume":"56","author":"L Thorel","year":"2024","unstructured":"Thorel L, Perreard M, Florent R, Divoux J, Coffy S, Vincent A, et al. Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology. Exp Mol Med. 2024;56(7):1531\u201351.","journal-title":"Exp Mol Med"},{"issue":"3","key":"2391_CR19","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ajpath.2017.11.013","volume":"188","author":"L Li","year":"2018","unstructured":"Li L, Qian M, Chen IH, Finkelstein D, Onar-Thomas A, Johnson M, et al. Acquisition of cholangiocarcinoma traits during advanced hepatocellular carcinoma development in mice. Am J Pathol. 2018;188(3):656\u201371.","journal-title":"Am J Pathol"},{"issue":"8","key":"2391_CR20","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1002\/ddr.22108","volume":"84","author":"SR Akash","year":"2023","unstructured":"Akash SR, Arnob M, Uddin MJ. FDA modernization act 2.0: an insight from nondeveloping country. Drug Dev Res. 2023;84(8):1572\u20137.","journal-title":"Drug Dev Res"},{"issue":"4","key":"2391_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/adt.2014.573","volume":"12","author":"R Edmondson","year":"2014","unstructured":"Edmondson R, Broglie JJ, Adcock AF, Yang L. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. 2014;12(4):207\u201318.","journal-title":"Assay Drug Dev Technol"},{"issue":"5","key":"2391_CR22","doi-asserted-by":"publisher","first-page":"677","DOI":"10.32604\/or.2023.029718","volume":"31","author":"MB Khawar","year":"2023","unstructured":"Khawar MB, Wang Y, Majeed A, Afzal A, Haneef K, Sun H. Mini-organs with big impact: organoids in liver cancer studies. Oncol Res. 2023;31(5):677\u201388.","journal-title":"Oncol Res"},{"key":"2391_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054529","author":"S De Siervi","year":"2023","unstructured":"De Siervi S, Turato C. Liver organoids as an in vitro model to study primary liver cancer. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24054529.","journal-title":"Int J Mol Sci"},{"key":"2391_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.216048","volume":"555","author":"L Chen","year":"2023","unstructured":"Chen L, Wei X, Gu D, Xu Y, Zhou H. Human liver cancer organoids: biological applications, current challenges, and prospects in hepatoma therapy. Cancer Lett. 2023;555: 216048.","journal-title":"Cancer Lett"},{"issue":"1","key":"2391_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2021.112987","volume":"411","author":"JH Yu","year":"2022","unstructured":"Yu JH, Ma S. Organoids as research models for hepatocellular carcinoma. Exp Cell Res. 2022;411(1): 112987.","journal-title":"Exp Cell Res"},{"key":"2391_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cells13201726","author":"C Airola","year":"2024","unstructured":"Airola C, Pallozzi M, Cesari E, Cerrito L, Stella L, Sette C, et al. Hepatocellular-carcinoma-derived organoids: innovation in cancer research. Cells. 2024. https:\/\/doi.org\/10.3390\/cells13201726.","journal-title":"Cells"},{"issue":"5","key":"2391_CR27","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s13402-022-00707-3","volume":"45","author":"L Xian","year":"2022","unstructured":"Xian L, Zhao P, Chen X, Wei Z, Ji H, Zhao J, et al. Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer. Cell Oncol (Dordr). 2022;45(5):1019\u201336.","journal-title":"Cell Oncol (Dordr)"},{"issue":"27","key":"2391_CR28","doi-asserted-by":"publisher","first-page":"e2302640","DOI":"10.1002\/advs.202302640","volume":"10","author":"Z Zou","year":"2023","unstructured":"Zou Z, Lin Z, Wu C, Tan J, Zhang J, Peng Y, et al. Micro-Engineered Organoid-on-a-Chip based on mesenchymal stromal cells to predict immunotherapy responses of HCC patients. Adv Sci (Weinh). 2023;10(27):e2302640.","journal-title":"Adv Sci (Weinh)"},{"key":"2391_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.slasd.2024.100201","volume":"30","author":"DA Close","year":"2025","unstructured":"Close DA, Johnston PA. Miniaturization and characterization of patient derived hepatocellular carcinoma tumor organoid cultures for cancer drug discovery applications. SLAS Discov. 2025;30: 100201.","journal-title":"SLAS Discov"},{"key":"2391_CR30","doi-asserted-by":"crossref","unstructured":"Zhang CY, Zhang XF, Yuan J, Gong YF, Tang H, Guo WY et al. Development and optimization of A human hepatocellular carcinoma Patient-Derived organoid model for potential target identification and drug discovery. J Vis Exp. 2023(198).","DOI":"10.3791\/65785"},{"issue":"2","key":"2391_CR31","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jcmgh.2020.09.003","volume":"11","author":"J Liu","year":"2021","unstructured":"Liu J, Li P, Wang L, Li M, Ge Z, Noordam L, et al. Cancer-associated fibroblasts provide a stromal niche for liver cancer organoids that confers trophic effects and therapy resistance. Cell Mol Gastroenterol Hepatol. 2021;11(2):407\u201331.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"9","key":"2391_CR32","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1038\/nprot.2016.097","volume":"11","author":"L Broutier","year":"2016","unstructured":"Broutier L, Andersson-Rolf A, Hindley CJ, Boj SF, Clevers H, Koo BK, et al. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat Protoc. 2016;11(9):1724\u201343.","journal-title":"Nat Protoc"},{"issue":"1","key":"2391_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/carcin\/bgy129","volume":"40","author":"W Cao","year":"2019","unstructured":"Cao W, Liu J, Wang L, Li M, Verstegen MMA, Yin Y, et al. Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors. Carcinogenesis. 2019;40(1):145\u201354.","journal-title":"Carcinogenesis"},{"issue":"5","key":"2391_CR34","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1002\/hep.29304","volume":"66","author":"YN Fan","year":"2017","unstructured":"Fan YN, Arechederra M, Richelme S, Daian F, Novello C, Calderaro J, et al. A Phosphokinome-Based screen uncovers new drug synergies for cancer driven by Liver-Specific gain of nononcogenic receptor tyrosine kinases. Hepatology. 2017;66(5):1644\u201361.","journal-title":"Hepatology"},{"issue":"4","key":"2391_CR35","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jhep.2020.11.008","volume":"74","author":"M Arechederra","year":"2021","unstructured":"Arechederra M, Bazai SK, Abdouni A, Sequera C, Mead TJ, Richelme S, et al. ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. J Hepatol. 2021;74(4):893\u2013906.","journal-title":"J Hepatol"},{"issue":"3","key":"2391_CR36","doi-asserted-by":"publisher","first-page":"112071","DOI":"10.1016\/j.isci.2025.112071","volume":"28","author":"F Cannet","year":"2025","unstructured":"Cannet F, Sequera C, Veloso PM, El Kaoutari A, Methia M, Richelme S, et al. Tracing specificity of immune landscape remodeling associated with distinct anticancer treatments. iScience. 2025;28(3):112071.","journal-title":"iScience"},{"issue":"9","key":"2391_CR37","doi-asserted-by":"publisher","first-page":"e1005533","DOI":"10.1371\/journal.pgen.1005533","volume":"11","author":"Y Fan","year":"2015","unstructured":"Fan Y, Richelme S, Avazeri E, Audebert S, Helmbacher F, Dono R, et al. Tissue-specific gain of RTK signalling uncovers selective cell vulnerability during embryogenesis. PLoS Genet. 2015;11(9):e1005533.","journal-title":"PLoS Genet"},{"key":"2391_CR38","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1038\/cddis.2011.11","volume":"2","author":"M Genestine","year":"2011","unstructured":"Genestine M, Caricati E, Fico A, Richelme S, Hassani H, Sunyach C, et al. Enhanced neuronal Met signalling levels in ALS mice delay disease onset. Cell Death Dis. 2011;2:e130.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2391_CR39","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1038\/s41467-018-05550-5","volume":"9","author":"M Arechederra","year":"2018","unstructured":"Arechederra M, Daian F, Yim A, Bazai SK, Richelme S, Dono R, et al. Hypermethylation of gene body CpG islands predicts high dosage of functional oncogenes in liver cancer. Nat Commun. 2018;9(1):3164.","journal-title":"Nat Commun"},{"key":"2391_CR40","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.isci.2019.10.015","volume":"21","author":"F Cassol","year":"2019","unstructured":"Cassol F, Portal L, Richelme S, Dupont M, Boursier Y, Arechederra M, et al. Tracking dynamics of spontaneous tumors in mice using photon-counting computed tomography. iScience. 2019;21:68\u201383.","journal-title":"iScience"},{"issue":"2","key":"2391_CR41","doi-asserted-by":"publisher","first-page":"100577","DOI":"10.1016\/j.xpro.2021.100577","volume":"2","author":"J Cui","year":"2021","unstructured":"Cui J, Guo W. Establishment and long-term culture of mouse mammary stem cell organoids and breast tumor organoids. STAR Protoc. 2021;2(2):100577.","journal-title":"STAR Protoc"},{"issue":"19","key":"2391_CR42","doi-asserted-by":"publisher","first-page":"9180","DOI":"10.7150\/thno.60503","volume":"11","author":"O Castellanet","year":"2021","unstructured":"Castellanet O, Ahmad F, Vinik Y, Mills GB, Habermann B, Borg JP, et al. Bcl-xl blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators. Theranostics. 2021;11(19):9180\u201397.","journal-title":"Theranostics"},{"issue":"3","key":"2391_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202003049","volume":"8","author":"F Lamballe","year":"2021","unstructured":"Lamballe F, Ahmad F, Vinik Y, Castellanet O, Daian F, Muller AK, et al. Modeling heterogeneity of Triple-Negative breast cancer uncovers a novel combinatorial treatment overcoming primary drug resistance. Adv Sci. 2021;8(3): 2003049.","journal-title":"Adv Sci"},{"issue":"11","key":"2391_CR44","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41419-022-05411-6","volume":"13","author":"C Sequera","year":"2022","unstructured":"Sequera C, Grattarola M, Holczbauer A, Dono R, Pizzimenti S, Barrera G, et al. MYC and MET cooperatively drive hepatocellular carcinoma with distinct molecular traits and vulnerabilities. Cell Death Dis. 2022;13(11):994.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2391_CR45","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1038\/s41598-017-18815-8","volume":"8","author":"MA Borten","year":"2018","unstructured":"Borten MA, Bajikar SS, Sasaki N, Clevers H, Janes KA. Automated brightfield morphometry of 3D organoid populations by OrganoSeg. Sci Rep. 2018;8(1):5319.","journal-title":"Sci Rep"},{"issue":"1","key":"2391_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09508-y","volume":"12","author":"S Price","year":"2022","unstructured":"Price S, Bhosle S, Goncalves E, Li X, McClurg DP, Barthorpe S, et al. A suspension technique for efficient large-scale cancer organoid culturing and perturbation screens. Sci Rep. 2022;12(1): 5571.","journal-title":"Sci Rep"},{"issue":"3","key":"2391_CR47","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","volume":"29","author":"I Pastushenko","year":"2019","unstructured":"Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212\u201326.","journal-title":"Trends Cell Biol"},{"issue":"207","key":"2391_CR48","doi-asserted-by":"publisher","first-page":"20230468","DOI":"10.1098\/rsif.2023.0468","volume":"20","author":"MS Shajib","year":"2023","unstructured":"Shajib MS, Futrega K, Davies AM, Franco RAG, McKenna E, Guillesser B, et al. A tumour-spheroid manufacturing and cryopreservation process that yields a highly reproducible product ready for direct use in drug screening assays. J R Soc Interface. 2023;20(207):20230468.","journal-title":"J R Soc Interface"},{"key":"2391_CR49","doi-asserted-by":"publisher","unstructured":"Sequera C, Grattarola M, Cannet F, Dobric A, Veloso PM, Methia M, et al. Lipid and cell cycling perturbations driven by the HDAC inhibitor romidepsin render liver cancer vulnerable to RTK targeting and immunologically active. Nature Communications. 2025. https:\/\/doi.org\/10.1038\/s41467-025-62934-0.","DOI":"10.1038\/s41467-025-62934-0"},{"issue":"4","key":"2391_CR50","first-page":"266","volume":"32","author":"K Duval","year":"2017","unstructured":"Duval K, Grover H, Han LH, Mou Y, Pegoraro AF, Fredberg J, et al. Modeling physiological events in 2D vs. 3D cell culture. Physiol (Bethesda). 2017;32(4):266\u201377.","journal-title":"Physiol (Bethesda)"},{"issue":"4","key":"2391_CR51","first-page":"910","volume":"14","author":"M Kapalczynska","year":"2018","unstructured":"Kapalczynska M, Kolenda T, Przybyla W, Zajaczkowska M, Teresiak A, Filas V, et al. 2D and 3D cell cultures - a comparison of different types of cancer cell cultures. Arch Med Sci. 2018;14(4):910\u20139.","journal-title":"Arch Med Sci"},{"key":"2391_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/ph17040529","author":"J Park","year":"2024","unstructured":"Park J, Koh I, Cha J, Oh Y, Shim JK, Kim H, et al. Comparison of glioblastoma cell culture platforms based on transcriptional similarity with paired tissue. Pharmaceuticals (Basel). 2024. https:\/\/doi.org\/10.3390\/ph17040529.","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02391-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02391-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02391-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:03:33Z","timestamp":1759413813000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-025-02391-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2391"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02391-w","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving the use of animals were performed in accordance with the European Community Council Directive of 22 September 2010 on the protection of animals used for experimental purposes (2010\/63\/EU). The experimental protocols were carried out in compliance with institutional Ethical Committee guidelines for animal research (comit\u00e9 d\u2019\u00e9thique pour l\u2019exp\u00e9rimentation animale \u2013 Comit\u00e9 d\u2019\u00e9thique de Marseille) and in compliance with French law, under an agreement number E1305521, Minist\u00e8re de l\u2019Enseignement Sup\u00e9rieur de la Recherche et de l\u2019Innovation. Mice were kept in a dedicated pathogen-free facility, with a light\/dark cycle, and in cages with an enriched environment. Mice received Safe Complete Care Competence (SAFE A04) as complete aliment ad libitum and were housed in environmentally enriched cages under pathogen-free conditions. The project authorization of Maina laboratory relevant to this study is APAFIS #8214-2016121417291352.v5, delivered by the \u201cMinist\u00e8re de l\u2019Enseignement Sup\u00e9rieur, de la Recherche et de l\u2019Innovation\u201d.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"410"}}